Biogen Reports Q3 2026 Revenue Growth Driven by Apellis Acquisition and Strong Growth Portfolio
Biogen (BIIB) reported strong third-quarter results for 2026, with total revenue reaching $2.8 billion, an 11% increase year-over-year. This growth was significantly bolstered by the acquisition of Apellis and a robust performance from its growth portfolio, which now accounts for 63% of core pharmaceutical revenue. Key drivers included LEQEMBI's in-market sales, which grew 67%, and significant gains in SPINRAZA and SKYCLARYS. Despite the top-line strength, Biogen reported a GAAP loss per share of $0.14 due to amortization costs and restructuring charges from the Apellis integration. However, management raised its full-year non-GAAP EPS guidance to a range of $12.20 to $13.00. The company is also aggressively managing debt, having repaid $600 million in term loans since the acquisition, with plans to clear remaining debt by 2027.
Topics: acquisition eps pharmaceuticals product performance revenue growth